Medpace Holdings, Inc. 10-K

Item 8. Financial Statements and Supplementary Data. Management's Report on Internal Control Over Financial Reporting Management of Medpace Holdings, Inc. (the “Company”) is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company, (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements in the consolidated financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022. In making these assessments, management used the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on management’s assessment and the criteria in the COSO framework, management has concluded that the Company’s internal control over financial reporting as of December 31, 2022 was effective. The effectiveness of the Company’s internal control over financial reporting has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report included herein. - 42 - Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Medpace Holdings, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Medpace Holdings, Inc. and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations , comprehensive income, shareholders' equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 14, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Revenue Recognition — Clinical Research– Refer to Note 2 to the financial statements Critical Audit Matter Description The Company recognizes contract revenue over the contract term as the service progresses, as the transfer of control to the customer is continuous. Substantially all of the Company’s clinical research contracts consist of a single performance obligation as the promise to transfer individual services described in the contracts are not separately identifiable from other promises in the contracts, and therefore not distinct. The accounting for these contracts involves judgment, particularly as it relates to the process of estimating costs to complete a contract for the performance obligation, which includes direct costs, reimbursable out-of-pocket costs, and reimbursable investigator site payments. Contract costs are recognized as incurred, and revenue recognition is based on cost incurred to date for the services provided compared to the total estimated costs to complete a contract. - 43 - Table of Contents Given the judgments necessary to estimate costs to complete a contract for the performance obligation used to recognize revenue for certain clinical research contracts over time, auditing such estimates required extensive audit effort due to the complexity of contracts and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures. How the Critical Audit Matter Was Addressed in the Audit Our audit procedures related to management’s estimates of costs to complete a contract for the performance obligation used to recognize revenue for clinical research contracts included the following, among others: • We tested the effectiveness of controls over revenue recognized throughout the contract term, including management’s controls over estimates of future services to be delivered and costs to be incurred under the contract. • We selected a sample of contracts and performed the following: ◦ Evaluated whether the contracts were properly included in management’s calculation of contract revenue based on the terms and conditions of each selected contract, including whether continuous transfer of control to the customer occurred as progress was made toward fulfilling the performance obligation. ◦ Compared the transaction prices to the consideration expected to be received based on current rights and obligations under the contracts and any pricing modifications and scope changes that were agreed upon with the customers. ◦ Tested management’s identification of distinct performance obligations by evaluating whether the progress of performance completed or delivered to date compared to total services to be delivered under the terms of the arrangement. ◦ Evaluated estimates of costs to complete a contract for the performance obligation by: ▪ Comparing costs incurred to date to the costs management estimated to be incurred to date. ▪ Evaluating management’s ability to achieve the estimates of total contract cost by performing corroborating inquiries with the Company’s project managers and financial analysts, and comparing the estimates to management’s work plans and cost estimates. ◦ Tested the mathematical accuracy of management’s calculation of revenue for the performance obligation. • We selected a sample of costs related to performance obligations and tested the accuracy and completeness of those costs incurred during the year. • We selected a sample of contracts and evaluated management’s ability to estimate total contract costs accurately by comparing actual costs to management’s historical estimates. /s/ Deloitte & Touche LLP Cincinnati, Ohio February 14, 2023 We have served as the Company's auditor since 2002. - 44 - Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Medpace Holdings, Inc. Opinion on Internal Control over Financial Reporting We have audited the internal control over financial reporting of Medpace Holdings, Inc. and subsidiaries (the “Company”) as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022, of the Company and our report dated February 14, 2023, expressed an unqualified opinion on those financial statements. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Deloitte & Touche LLP Cincinnati, Ohio February 14, 2023 - 45 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share amounts) As Of December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 28,265 $ 461,304 Accounts receivable and unbilled, net (includes $ 7.7 million and $ 2.7 million with related parties at December 31, 2022 and 2021, respectively) 253,404 186,432 Prepaid expenses and other current assets 52,293 43,176 Total current assets 333,962 690,912 Property and equipment, net 109,849 93,153 Operating lease right-of-use assets 139,068 129,558 Goodwill 662,396 662,396 Intangible assets, net 38,008 41,360 Deferred income taxes 48,083 25,134 Other assets 21,129 17,422 Total assets $ 1,352,495 $ 1,659,935 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable (includes $ 0.3 million with related parties at December 31, 2022 and 2021, respectively) $ 33,069 $ 25,678 Accrued expenses 210,125 159,286 Advanced billings (includes $ 8.8 million and $ 8.3 million with related parties at December 31, 2022 and 2021, respectively) 462,729 344,641 Short-term debt 50,000 — Other current liabilities (includes $ 12.5 million with related parties at December 31, 2022, respectively) 47,547 27,612 Total current liabilities 803,470 557,217 Operating lease liabilities 138,867 130,965 Deferred income tax liability 1,070 1,080 Other long-term liabilities 22,701 17,745 Total liabilities 966,108 707,007 Commitments and contingencies (see Note 12) Shareholders’ equity: Preferred stock - $ 0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021, respectively — — Common stock - $ 0.01 par-value; 250,000,000 shares authorized at December 31, 2022 and 2021, respectively; 31,091,694 and 36,006,778 shares issued and outstanding at December 31, 2022 and 2021, respectively 309 360 Treasury stock - 71,573 and 180,000 shares at December 31, 2022 and 2021, respectively ( 12,497 ) ( 5,427 ) Additional paid-in capital 770,794 727,857 (Accumulated deficit) Retained earnings ( 359,827 ) 234,984 Accumulated other comprehensive loss ( 12,392 ) ( 4,846 ) Total shareholders’ equity 386,387 952,928 Total liabilities and shareholders’ equity $ 1,352,495 $ 1,659,935 See notes to consolidated financial statements. - 46 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share amounts) Year Ended December 31, 2022 2021 2020 Revenue, net (includes $ 55.4 million, $ 34.5 million and $ 15.9 million with related parties for the years ended December 31, 2022, 2021 and 2020, respectively) $ 1,459,996 $ 1,142,377 $ 925,925 Operating expenses: Direct service costs, excluding depreciation and amortization 534,887 441,090 354,426 Reimbursed out-of-pocket expenses 492,671 373,132 292,773 Total direct costs 1,027,558 814,222 647,199 Selling, general and administrative 131,400 108,421 92,156 Depreciation 18,989 16,005 11,652 Amortization 3,352 5,114 7,876 Total operating expenses 1,181,299 943,762 758,883 Income from operations 278,697 198,615 167,042 Other income, net: Miscellaneous income, net 7,068 3,342 1,183 Interest (expense) income, net ( 2,905 ) ( 105 ) 307 Total other income, net 4,163 3,237 1,490 Income before income taxes 282,860 201,852 168,532 Income tax provision 37,492 20,004 23,148 Net income $ 245,368 $ 181,848 $ 145,384 Net income per share attributable to common shareholders: Basic $ 7.57 $ 5.06 $ 4.07 Diluted $ 7.28 $ 4.81 $ 3.84 Weighted average common shares outstanding: Basic 32,388 35,862 35,635 Diluted 33,671 37,697 37,708 See notes to consolidated financial statements. - 47 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Amounts in thousands) Year Ended December 31, 2022 2021 2020 Net income $ 245,368 $ 181,848 $ 145,384 Other comprehensive (loss) income Foreign currency translation adjustments, net of taxes ( 7,546 ) ( 4,715 ) 2,610 Comprehensive income $ 237,822 $ 177,133 $ 147,994 See notes to consolidated financial statements. - 48 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Amounts in thousands) Common Stock Treasury Stock Additional Paid-In Capital (Accumulated Deficit) Retained Earnings Accumulated Other Comprehensive Loss Total BALANCE — December 31, 2019 $ 360 $ ( 6,030 ) $ 666,585 $ 68,109 $ ( 2,741 ) $ 726,283 Net income 145,384 145,384 Foreign currency translation 2,610 2,610 Stock-based compensation expense 13,784 13,784 Stock options exercised 5 452 15,535 15,992 Repurchases of common stock ( 10 ) $ ( 98,264 ) ( 98,274 ) BALANCE — December 31, 2020 $ 355 $ ( 5,578 ) $ 695,904 $ 115,229 $ ( 131 ) $ 805,779 Net income 181,848 181,848 Foreign currency translation ( 4,715 ) ( 4,715 ) Stock-based compensation expense 14,469 14,469 Stock options exercised 8 151 17,484 17,643 Repurchases of common stock ( 3 ) $ ( 62,093 ) ( 62,096 ) BALANCE — December 31, 2021 $ 360 $ ( 5,427 ) $ 727,857 $ 234,984 $ ( 4,846 ) $ 952,928 Net income 245,368 245,368 Foreign currency translation ( 7,546 ) ( 7,546 ) Stock-based compensation expense 21,412 21,412 Stock options exercised 6 1,746 21,525 ( 1,203 ) 22,074 Repurchases of common stock ( 57 ) ( 14,243 ) ( 833,549 ) ( 847,849 ) Retirement of treasury stock 5,427 ( 5,427 ) — BALANCE — December 31, 2022 $ 309 $ ( 12,497 ) $ 770,794 $ ( 359,827 ) $ ( 12,392 ) $ 386,387 See notes to consolidated financial statements. - 49 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands) Year Ended December 31, 2022 2021 2020 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 245,368 $ 181,848 $ 145,384 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 18,989 16,005 11,652 Amortization 3,352 5,114 7,876 Stock-based compensation expense 21,412 14,469 13,784 Noncash lease expense 18,015 16,288 13,924 Deferred income tax (benefit) provision ( 23,014 ) ( 37,112 ) 527 Amortization and adjustment of deferred credit ( 620 ) ( 668 ) ( 706 ) Other ( 1,507 ) 676 ( 22 ) Changes in assets and liabilities: Accounts receivable and unbilled, net ( 66,920 ) ( 24,982 ) ( 5,530 ) Prepaid expenses and other current assets ( 10,175 ) ( 9,134 ) ( 3,724 ) Accounts payable 6,431 1,866 ( 2,597 ) Accrued expenses 52,476 26,156 24,231 Advanced billings 118,088 88,977 63,407 Lease liabilities ( 15,899 ) ( 15,632 ) ( 11,506 ) Other assets and liabilities, net 22,054 ( 544 ) 1,976 Net cash provided by operating activities 388,050 263,327 258,676 CASH FLOWS FROM INVESTING ACTIVITIES: Property and equipment expenditures ( 36,879 ) ( 28,271 ) ( 31,340 ) Other ( 1,863 ) ( 3,093 ) 126 Net cash used in investing activities ( 38,742 ) ( 31,364 ) ( 31,214 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from stock option exercises 22,074 17,643 15,992 Repurchases of common stock ( 847,849 ) ( 62,096 ) ( 98,274 ) Proceeds from revolving loan 324,200 — — Payments on revolving loan ( 274,200 ) — — Net cash used in financing activities ( 775,775 ) ( 44,453 ) ( 82,282 ) EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ( 6,572 ) ( 3,972 ) 666 (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ( 433,039 ) 183,538 145,846 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period 461,304 277,766 131,920 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period $ 28,265 $ 461,304 $ 277,766 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION— Cash paid during the period for income taxes $ 50,164 $ 56,243 $ 23,105 Cash paid during the period for interest $ 2,935 $ 123 $ 104 Acquisition of property and equipment—non-cash $ 7,838 $ 6,352 $ 18,980 See notes to consolidated financial statements. - 50 - Table of Contents MEDPACE HOLDINGS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS As of December 31, 2022 and 2021, and for the Years Ended December 31, 2022, 2021 and 2020 1. BASIS OF PRESENTATION Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Share Repurchases In 2018, the Board of Directors approved a stock repurchase program which has been amended several times to increase the aggregate amount of the stock repurchase authorization. For the year ended December 31, 2022, the Company repurchased 5,463,244 shares for $ 800.5 million under this repurchase program. For the year ended December 31, 2021, the Company repurchased 377,783 shares for $ 62.1 million. For the year ended December 31, 2020, the Company repurchased 1,183,095 shares for $ 98.3 million. As of June 30, 2022, the Company completed all authorized share repurchases under this repurchase program. In the fourth quarter of 2022, the Board approved a new stock repurchase program of up to $ 500.0 million. For the year ended December 31, 2022, the Company repurchased 228,247 shares for $ 47.2 million under the new repurchase program. As of December 31, 2022, we have remaining authorization of $ 452.8 million under the new repurchase program. Repurchases under the share repurchase programs are executed in the open market or negotiated transactions under trading plans established pursuant to Rule 10b5-1. The Company constructively retired the repurchased shares associated with these approved share repurchase programs, except for a small portion which were retained as Treasury Shares on the consolidated statements of shareholders' equity. Retired share repurchase amounts paid in excess of par value are reflected within Accumulated deficit/Retained earnings in the Company’s consolidated balance sheets. The repurchase programs may be suspended or discontinued at any time without notice. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and include the accounts and operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant items that are subject to management estimates and assumptions include revenue, net, allowances for doubtful accounts, acquisition purchase price allocations, long-lived asset impairment and useful lives, exit liabilities, stock-based compensation, uncertain income tax positions and contingencies. - 51 - Table of Contents Reportable Segments The Company emphasizes its full service outsourcing model, providing services focused on the development, management and execution of clinical trials. As part of this full service approach, the Company utilizes centralized systems, customer interface technology, support functions and processes that cross service offerings and align resources to deliver efficient clinical trial services. Given the full service approach, the chief executive officer, who is the chief operating decision maker (“CODM”) assesses the allocation of resources based on key metrics including revenue, backlog, and net awards by service offering and consolidated profitability and consolidated cash flows. Based on the Company’s full service model, internal management and reporting structure, and key metrics used by the CODM to make resource allocation decisions, management has determined that the Company’s operations consist of a single operating segment. Therefore, results of operations are presented as a single reportable segment. Foreign Currencies Assets and liabilities recorded in foreign currencies on foreign subsidiary financial statements are translated at the exchange rate on the balance sheet date, while equity accounts are translated at historical exchange rates. Revenue and expenses are recorded at average rates of exchange during the year. Translation adjustments are recorded to Accumulated other comprehensive loss in the consolidated statements of shareholders’ equity and consolidated statements of comprehensive income. Separately, net realized gains and losses on foreign currency transactions are included in Miscellaneous income, net, on the consolidated statements of operations. Foreign currency transactions resulted in a net gain of $ 3.9 million, $ 2.8 million, and $ 0.5 million during the years ended December 31, 2022, 2021, and 2020, respectively. Revenue Recognition The Company generally enters into contracts with customers to provide services ranging in duration from a few months to several years. The contract terms generally provide for payments based on a fixed fee or unit-of-service arrangement. The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue on contracts is recognized when or as the Company satisfies the contract performance obligations, at the amount that reflects the Company’s cumulative progress toward delivery of the performance obligation. This progress assessment is applied to the amount of consideration to which the Company expects to be paid for delivery of the performance obligation. The Company’s performance obligations are generally satisfied over time and related revenue is recognized as services are provided to meet these obligations. Contract Assumptions An arrangement is accounted for as a contract within the scope of ASC 606 when the Company and its customers approve the contract, are committed to perform their respective obligations, each party can identify its rights regarding the goods or services to be transferred, commercial substance is present, and it is probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. For the Company’s services to meet this criteria, contracts generally need to be written, pending regulatory hurdles required to commence work must be cleared, the study protocol must be completed, the customer must have adequate funding or reasonable path to funding to execute the contracted portion of the study, and the study must be actively moving forward. Once these criteria have been met, it is deemed that the Company and its customers are committed to perform their respective obligations. Depending on the timing of when these criteria are met, revenue recognition may vary significantly on a period over period basis. Accounting for contracts performed over a period of time involves the use of various assumptions to estimate total contract revenue and costs. The Company estimates expected costs to complete a contract and recognizes contracted revenue over the life of the contract as those costs are incurred. Cost estimates are based on a detailed project budget and are developed based on many variables, including, but not limited to, the scope of the work, the complexity of the study, the participating geographic locations and the Company’s historical experience. To assist with the estimation of costs expected at completion over the life of a project, regular contract reviews are performed in which performance to date is compared to the most current estimate to complete assumptions. The reviews include an assessment of costs incurred to date compared to expectations based on budget assumptions and other - 52 - Table of Contents circumstances specific to the project. The total estimated costs necessary to complete is updated and any revisions to the existing cost estimate results in cumulative adjustments to the amount of revenue recognized in the period in which the revisions are identified. In the case of cost estimates related to activities legally contracted as reimbursable in nature, including but not limited to investigator fee activity, these estimates also influence the Company’s assumed contract value and assumed remaining performance obligations. Because of the uncertainties inherent in estimating the costs necessary to fulfill contractual obligations, it is possible that estimates may change in the near term, resulting in a material change in revenue reported. Contracts generally provide for pricing modifications upon scope of work changes. The Company recognizes revenue, at an amount to which it expects to be entitled, related to work performed in connection with scope changes when the underlying services are performed and a binding contractual commitment has been established with the customer. If the Company’s customers do not agree to contract changes upon changes in the Company’s scope of work, the Company could be exposed to cost overruns and reduced contract profitability. Costs are not deferred in anticipation of contracts being awarded or amendments being finalized, but are expensed as incurred. Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. These contracts require payment of fees for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are agreed to with the customer based on remaining work to be performed. These amounts are included in revenue when the Company believes the amount can be estimated reliably and its realization is probable. In evaluating the probability of recognition, the Company considers the contractual basis for the settlement amount and the objective evidence available to support the amount. Certain contracts contain volume rebate arrangements with our customers that provide for rebates if certain specified spending thresholds are met. These obligations are considered as a reduction in revenue when it appears probable that the arrangement thresholds will be met, which can be at contract inception. Total revenue is presented net of rebates of $ 7.9 million, $ 7.2 million and $ 4.8 million in the consolidated statements of operations during the years ended December 31, 2022, 2021 and 2020, respectively. The Company occasionally enters into incentive fee arrangements with customers that provide for additional compensation if certain defined contractual milestones or performance thresholds are met. These additional fees are included in the estimated transaction price when there is a basis to reasonably estimate the amount of the fee and when achievement of the incentive milestone is deemed probable. These estimates are based on anticipated performance, the Company’s best judgment at the time or ultimately, upon achievement of the threshold or milestone. The Company records revenue net of any tax assessments by governmental authorities that are imposed and concurrent with specific revenue generating transactions. Performance Obligations Substantially all of the Company’s contracts consist of a single performance obligation, as the promise to transfer the individual services described in the contracts are not separately identifiable from other promises in the contracts, and therefore not distinct. Revenue recognition is determined by assessing the progress of performance completed or delivered to date compared to total services to be delivered under the terms of the arrangement. The measures utilized to assess progress on the satisfaction of performance are specific to the performance obligation identified in the contract. For the majority of the Company’s contract performance obligations, it utilizes the input method of cost to cost to measure progress, as the Company has determined that it is the most consistent measure of progress among contract tasks and represents the most faithful depiction of the transfer of services over the contract life. Under this method, the Company determines cost incurred to date for the services it provides compared to the total estimated costs at completion. For certain other contractual performance obligations, the Company has determined that an output method is the best measure of progress. These relate to certain unitized contracts, and the Company recognizes revenue in the period in which the unit is delivered compared to total contracted units. As of December 31, 2022 and 2021, the Company had approximately $ 2.7 billion and $ 2.1 billion of performance obligations remaining to be performed for active projects. - 53 - Table of Contents Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The cash and cash equivalent balances are held and maintained with financial institutions with reputable credit ratings and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company generally does not require collateral or other securities to support customer receivables. In the years ended December 31, 2022, 2021 and 2020, credit losses have been immaterial and within management’s expectations. At December 31, 2022 and 2021, there were no customers accounting for more than 10% of the Company’s accounts receivable. Costs and Expenses The Company incurs costs associated with service delivery including direct labor and related employee benefits, laboratory supplies, and other expenses. These costs are recorded in Direct service costs, excluding depreciation and amortization as a component of Total direct costs in the accompanying consolidated statements of operations. In addition, the Company incurs expenses on behalf of its customers for various project expenditures including, but not limited to, investigator site payments, travel, meetings, printing, and shipping and handling fees that are reimbursed by its customers at cost. These costs are included in Reimbursable out-of-pocket expenses as a component of Total direct costs in the accompanying consolidated statements of operations. Total direct costs are expensed as incurred and are not deferred in anticipation of contracts being awarded or finalization of changes in scope. Selling, general and administrative includes administrative payroll and related employee benefits, sales and marketing expenses, administrative travel, and other expenses not directly related to service delivery. Rent, utilities, supplies, and software license expenses are allocated between Total direct costs, and Selling, general and administrative based on the estimated contribution among service delivery and support function efforts on a percentage basis. Depreciation and amortization is reported separately in the accompanying consolidated statements of operations. Costs of sales and marketing activities not subject to recovery pursuant to customer contracts, such as feasibility assessments and negotiation of contracts, are expensed as incurred and recorded as a component of Selling, general and administrative in the accompanying consolidated statements of operations. Advertising expenses are recorded as a component of Selling, general and administrative expenses in the accompanying consolidated statements of operations. Total advertising expenses of $ 1.3 million, $ 1.2 million and $ 0.7 million were incurred during the years ended December 31, 2022, 2021 and 2020, respectively. Income Taxes The Company’s consolidated US federal income tax return is comprised of its US subsidiaries, one of its foreign branches located in Korea and certain foreign subsidiaries. The Company provides for income taxes on all transactions that have been recognized in the consolidated financial statements in accordance with accounting guidance governing income tax accounting. Accordingly, the impact of changes in income tax laws on deferred tax assets and deferred tax liabilities are recognized in net earnings in the period during which such changes are enacted. The Company records deferred tax assets and liabilities based on temporary differences between the financial statement bases and tax bases of assets and liabilities. Deferred tax assets are recorded for tax benefit carryforwards using tax rates anticipated to be in effect in the year in which the temporary differences are expected to reverse. If it does not appear more likely than not that the full value of a deferred tax asset will be realized, the Company records a valuation allowance against the deferred tax asset, with an offsetting charge to the Company’s income tax provision or benefit. The value of the Company’s deferred tax assets is estimated based on, among other things, the Company’s ability to generate a sufficient level of future taxable income. In estimating future taxable income, the Company has considered both positive and negative evidence, such as historical and forecasted results of operations, and has considered the implementation of prudent and feasible tax planning strategies. The Company’s accounting position is that unremitted foreign earnings are indefinitely reinvested. Therefore, the Company has not recorded deferred foreign withholding taxes on the unremitted foreign earnings. Refer to Note 11 for further information regarding this assertion. The Company follows accounting guidance related to accounting for uncertainty in income taxes which requires significant judgment in determining what constitutes an individual tax position as well as assessing the possible outcome of each tax - 54 - Table of Contents position. Changes in judgments as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate, and, consequently, the Company’s consolidated financial results. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company determines its liability for uncertain tax positions globally. If the payment of these amounts ultimately proves to be unnecessary, the reversal of liabilities would result in tax benefits being recognized in the period when it is determined the liabilities are no longer necessary. If the calculation of the liability related to uncertain tax positions proves to be more or less than the ultimate assessment, a tax expense or tax benefit would result. Interest and penalties associated with uncertain tax positions are recognized as components of the Company’s Income tax provision. Stock-Based Compensation The Company has stock-based employee compensation plans for which it incurs compensation expense. Equity Awards In connection with the Company's initial public offering (IPO), the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested common shares, stock options, stock appreciation rights (SARs), restricted stock awards (RSAs), restricted stock units (RSUs), or other cash based or stock dividend equivalent awards. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of our common stock at the date of grant and option terms are not expected to exceed ten years . All outstanding Awards under the 2016 Plan are equity classified awards. The Company created the 2014 Plan, providing for the future issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock (the “2014 Plan Awards”). The 2014 Plan Awards were subject to either equity or liability-classification pursuant to the terms of the participant’s award agreement and the 2014 Plan based on accounting guidance which governs such transactions. All outstanding Awards under the 2014 Plan are equity classified awards in the periods presented. There were no outstanding awards under the 2014 Plan as of December 31, 2022. Stock-based compensation expense for both the 2016 Plan and 2014 Plan is calculated using the fair value method on the grant date. The Company expenses stock-based compensation over the term of the award based on the vesting described in the award agreement. Stock-based compensation expense is allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations based on the underlying classification and scope of work for the employees receiving the Awards. Net Income Per Share Basic and diluted earnings or loss per share (EPS) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. The Company’s RSAs are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term. The computation of diluted EPS includes additional common shares, such as unvested RSUs and stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding. This assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect. - 55 - Table of Contents The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2022, 2021 and 2020 (in thousands, except for earnings per share): Year Ended December 31, 2022 2021 2020 Weighted-average shares: Common shares outstanding 32,388 35,862 35,635 RSAs 21 90 112 Total weighted-average shares 32,409 35,952 35,747 Earnings per common share—Basic Net income $ 245,368 $ 181,848 $ 145,384 Less: Undistributed earnings allocated to RSAs ( 157 ) ( 458 ) ( 459 ) Net income available to common shareholders—Basic $ 245,211 $ 181,390 $ 144,925 Net income per common share—Basic $ 7.57 $ 5.06 $ 4.07 Basic weighted-average common shares outstanding 32,388 35,862 35,635 Effect of diluted shares 1,283 1,835 2,073 Diluted weighted-average shares outstanding 33,671 37,697 37,708 Net income per common share—Diluted $ 7.28 $ 4.81 $ 3.84 For the years ended December 31, 2022, 2021 and 2020, the computation of diluted EPS excludes the effect of (in thousands) 9 , 9 and 204 stock options, respectively, due to each respective period’s average fair value of the Company’s common stock not exceeding the exercise prices. Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses, and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of December 31, 2022. There were no transfers between Level 1, Level 2, or Level 3 during the years ended December 31, 2022, 2021 and 2020. Cash and Cash Equivalents, including Restricted Cash Cash and cash equivalents, including restricted cash, are invested in demand deposits and money market funds, all of which have an original maturity of three months or less. Restricted cash consists of customer funds received in advance and subject to specific restrictions, as well as amounts placed in escrow for contingent payments resulting from acquisitions or other contractual arrangements. - 56 - Table of Contents Accounts Receivable and Unbilled, Net Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled services represent revenue recognized to date that is currently not billable to the customer pursuant to contractual terms. In general, amounts become billable upon the achievement of negotiated contractual events or in accordance with predetermined payment schedules. Amounts classified to unbilled services are those billable to customers within one year from the respective balance sheet date. The Company grants credit terms to its customers prior to signing a service contract and monitors the creditworthiness of its customers on an ongoing basis. The Company maintains an allowance for doubtful accounts based on specific identification of accounts receivable that are at risk of not being collected. Uncollectible accounts receivable are written off only after all reasonable collection efforts have been exhausted. Moreover, in some cases the Company requires advance payment from its customers for a portion of the study contract price upon the signing of a service contract. These advance payments are deferred and recognized as revenue as services are performed. Inventory Inventory, which consists primarily of laboratory supplies, is valued at the lower of cost or market. Inventory is stated at purchased cost using the first-in, first out (FIFO) cost method. The inventory balance is included in Prepaid expenses and other current assets in the consolidated balance sheets. Property and Equipment Property and equipment is recorded at cost. Depreciation is provided on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone, and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years for buildings. The Company capitalizes costs of computer software developed for internal use and amortizes these costs on a straight-line basis over the estimated useful life, not to exceed three years . Leasehold improvements are capitalized and amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term. Repairs and maintenance are expensed as incurred. Leases The Company enters into contracts to lease facilities and equipment to be used in its operations. At contract inception, the Company determines whether a contract contains a lease within the scope of Accounting Standard Codification Topic 842, Leases (ASC 842), and determines the appropriate classification of the lease as either operating or finance. Contracts containing operating leases are recorded on the consolidated balance sheets within Operating lease right-of-use (ROU) assets, Other current liabilities, and Operating lease liabilities. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future lease payments over the lease term as of the lease commencement date. In addition, operating ROU assets also include lease payments made and exclude lease incentives and initial direct costs incurred. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term within Total direct costs and Selling, general, and administrative expenses. Variable lease costs are primarily related to adjustments for inflation, common area maintenance and property tax and are recognized within Total direct costs and Selling, general and administrative expenses. Contracts containing finance leases are recognized initially in the same manner as Operating lease ROU assets and liabilities; however, they are recorded on the consolidated balance sheets within Property and equipment, net, Other current liabilities, and Other long-term liabilities. Finance lease assets are subsequently amortized on a straight line basis over the lease term within Depreciation expense, while the lease liability is accreted within Interest expense, net utilizing the discount rate determined at lease commencement and reduced by periodic lease payments over the lease term. Currently, the Company does not have any finance leases. The discount rate utilized in determining the present value of future payments for both operating and finance leases, unless implicit in the lease contract, is determined based on the Company’s collateralized incremental borrowing rate based on the information available at lease commencement. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as determined at lease commencement. - 57 - Table of Contents Many of our lease agreements have both lease and non-lease components, which the Company has elected to treat as a single lease component for recognition purposes. The Company may enter into short-term leases (leases with a lease term of less than one year), which it has elected not to capitalize as assets and liabilities on the consolidated balance sheets, but instead recognizes lease payments within Total direct costs and Selling, general, and administrative expenses on a straight line basis over the lease term. Goodwill and Intangible Assets Goodwill Goodwill represents the excess of purchase price over the fair value of net assets acquired in business combinations. The carrying value of goodwill is reviewed at least annually for impairment, or as indicators of potential impairment are identified, at the reporting unit level. The reporting units are Phase I-IV clinical research services and Laboratories as of December 31, 2022. The Company performs its annual impairment tests during the fourth quarter each year, comparing the fair value of each of our reporting units with its carrying amount, inclusive of goodwill. A goodwill impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. Fair value is estimated using a combination of the income approach, a discounted cash flow analysis, and the market approach, utilizing the guideline company method. There was no indication of impairment related to goodwill based on the fourth quarter 2022 assessment. Intangible Assets The Company has an indefinite lived intangible asset related to its trade name. The carrying value of the trade name asset is reviewed at least annually for impairment, or as indicators of potential impairment are identified. The Company performs its annual impairment test in the fourth quarter each year in conjunction with its annual assessment of goodwill. The assessment consists of comparing the carrying value of the indefinite lived intangible asset to its estimated fair value, utilizing the relief from royalty method, an income approach valuation. There was no indication of impairment related to the trade name asset based on the fourth quarter 2022 assessment. Finite-lived intangible assets consist mainly of the value assigned to customer relationships and developed technologies. Finite-lived intangible assets are amortized straight-line or using an accelerated method over their estimated useful lives of fifteen years . Impairment of Long-Lived Assets Long-lived assets, primarily property and equipment and finite-lived intangible assets, are reviewed for impairment and the reasonableness of the estimated useful lives whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable or that a change in useful life may be appropriate. Recoverability for long-lived assets is determined by comparing the forecasted undiscounted cash flows of the operation to which the assets relate to the carrying amount of the assets. If the undiscounted cash flows are less than the carrying amount of the assets, then the Company reduces the carrying value of the assets to estimated fair values, which are primarily based upon forecasted discounted cash flows. Fair value of long-lived assets is determined based on a combination of discounted cash flows and market multiples. Advanced Billings Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized. Recently Adopted Accounting Standards In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for fiscal years - 58 - Table of Contents beginning after December 15, 2019 with early adoption permitted. The Company adopted this standard in the first quarter of 2020 and it had no material impact to the consolidated financial statements. In November 2021, the FASB issued ASU 2021-10, "Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance" which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity's financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The guidance is effective for annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this standard on a prospective basis in the fourth quarter of 2022. The Company receives global government incentives with domestic and foreign governments. The incentives come in various arrangements, but consist primarily in the form of tax credits, economic development grants and property tax abatement credits. Tax credits are available to the Company, in certain jurisdictions for qualifying research and development spend as well as for certain employment related milestone agreements. These tax credits are recorded on a jurisdiction-by-jurisdiction basis upon the first instance of the credit being monetized. Upon achieving a history of monetization in a jurisdiction, income is typically estimated as the activities or contractual requirements defined in the credit agreements occur. Depending on the jurisdiction rules, credits can be monetized immediately or up to 3 years after the credits have been submitted to the relevant taxing agencies. The Company receives grants from certain jurisdictions for economic development projects, based on job growth, employee retention and capital investment commitments. These grant funds are reimbursed to the Company upon achieving certain milestones and recognized as eligible costs are incurred. Property tax abatement credits are available to the Company in certain jurisdictions that reduce the cost of renting or owning real and business personal property. These credits are monetized through reductions to the real estate tax liability at the time payments are due and recognized as real estate taxes are incurred. Government incentives are recorded in accordance with their purpose, net of fees incurred to monetize the benefit, as a reduction of expense within Selling, general and administrative in the consolidated statements of operations. The Company recognized government assistance income, net of $ 15.4 million during the year ended December 31, 2022. Government assistance receivables are recorded in the consolidated balance sheets based on the expected timing of monetizing the benefit. Government assistance receivables recorded on the December 31, 2022 consolidated balance sheets are expected to be recovered through 2026. The Company recorded receivables related to government assistance programs as of December 31, 2022 of $ 11.3 million in Prepaid expenses and other current assets and $ 7.1 million in Other assets. 3. CONTRACT ASSETS AND CONTRACT LIABILITIES Contract assets and liabilities are reflected in the Company’s consolidated balance sheets within the accounts reflected below. Contract Assets Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled represents revenue recognized to date that has not been billed or is not yet contractually billable to the customer. In general, amounts become billable upon the achievement of negotiated contractual events, in accordance with predetermined payment schedules or when a reimbursable expense has been incurred. Amounts classified to unbilled are those billable to customers within one year from the respective balance sheet date. Accounts receivable and unbilled, net consisted of the following at December 31 (in thousands): 2022 2021 Accounts receivable $ 213,169 $ 150,496 Unbilled receivables 40,405 36,107 Less: allowance for doubtful accounts ( 170 ) ( 171 ) Total accounts receivable and unbilled, net $ 253,404 $ 186,432 - 59 - Table of Contents Contract Liabilities Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized. During the year ended December 31, 2022, the Company recognized approximately $ 293.6 million of revenue that was included in the Advanced billings balance at the beginning of the year. Advanced billings consisted of the following at December 31 (in thousands): 2022 2021 Advanced billings $ 462,729 $ 344,641 A rollforward of allowance for doubtful account activity is as follows: Year Ended December 31, 2022 2021 2020 Allowance for doubtful accounts - beginning balance $ ( 171 ) $ ( 346 ) $ ( 583 ) Current year provision — ( 11 ) ( 167 ) Write-offs, recoveries and the effects of foreign currency exchange 1 186 404 Allowance for doubtful accounts - ending balance $ ( 170 ) $ ( 171 ) $ ( 346 ) 4. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following at December 31, (in thousands): 2022 2021 Land $ 2,410 $ 2,446 Equipment 31,851 27,976 Furniture, fixtures, and leasehold improvements 87,543 66,295 Computer hardware, software, and phone equipment 26,049 23,308 Buildings 13,594 13,770 Construction-in-progress 10,518 10,459 Property and equipment at cost 171,965 144,254 Less: Accumulated depreciation ( 62,116 ) ( 51,101 ) Property and equipment, net $ 109,849 $ 93,153 Depreciation expense was $ 19.0 million, $ 16.0 million and $ 11.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. 5. GOODWILL AND INTANGIBLE ASSETS Goodwill Total assets reflected on the balance sheet and not remeasured to fair value on a recurring basis, identified as Level 3 measurements, as of December 31, 2022 are $ 694.0 million, comprised of $ 662.4 million of goodwill and $ 31.6 million of identified indefinite-lived intangible assets. Accumulated goodwill impairment losses to date amounts to $ 9.3 million, all of which was recognized in the year ended December 31, 2015. - 60 - Table of Contents Intangible Assets, Net Intangible assets, net consisted of the following at December 31 (in thousands): 2022 2021 Intangible assets: Finite-lived intangible assets: Carrying amount: Customer relationships 145,051 145,051 Accumulated amortization: Customer relationships ( 138,689 ) ( 135,337 ) Total finite-lived intangible assets, net 6,362 9,714 Trade name (indefinite-lived) 31,646 31,646 Total intangible assets, net $ 38,008 $ 41,360 As of December 31, 2022, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands): Amortization 2023 $ 2,199 2024 1,443 2025 946 2026 620 2027 577 2028 577 $ 6,362 6. ACCRUED EXPENSES Accrued expenses consisted of the following at December 31 (in thousands): 2022 2021 Employee compensation and benefits $ 71,197 $ 57,846 Project related reimbursable expenses 128,416 91,839 Other 10,512 9,601 Total accrued expenses $ 210,125 $ 159,286 7. SHORT-TERM DEBT Debt consisted of the following at December 31 (in thousands): 2022 2021 Revolving credit facility $ 50,000 $ — Short-term debt $ 50,000 $ — Principal payments on debt are due as follows (in thousands): 2023 50,000 Total $ 50,000 - 61 - Table of Contents On September 30, 2019 (the “Closing Date”), the Company obtained an unsecured credit facility in an aggregate principal amount up to $ 50.0 million (as amended from time to time, the “Credit Facility”) through its wholly owned subsidiaries, Medpace, Inc., as borrower (the “Borrower”), and Medpace IntermediateCo, Inc., as guarantor (the “Guarantor”). On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On December 27, 2021, the Company entered into Amendment No. 3 to the Credit Facility, which extends the expiration date of the revolving credit note to March 31, 2023 and adds provisions for alternative rates of interest as a result of global reference rate initiatives and removes the ability to obtain advances in any currency other than U.S. Dollars. After the LIBOR cessation date of December 31, 2021, the Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) and the benchmark replacement adjustment plus 100 basis points ( 1.00 %). On March 15, 2022, the Company entered into Amendment No. 4 to the Loan Agreement, which increased the aggregate principal amount that may be borrowed under the facility’s line of credit to up to $ 250.0 million. As of December 31, 2022, the Credit Facility interest rate was 5.3 %. The Loan Agreement contains other customary loan terms, representations and warranties, and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Loan Agreement contains certain events of default, including, among others, non-payment of principal or interest and breach of the covenants. As of December 31, 2022 and 2021, respectively, there were $ 0.2 million in letters of credit outstanding related to certain operating lease obligations, which are secured by the Credit Facility. 8. LEASES The Company enters into leases for real estate and equipment. Real estate leases are for our corporate office space and laboratories around the world. Real estate leases have remaining lease terms of less than one year to 18 years. Many of the Company’s leases include options to extend the leases on a month to month basis or for set periods for up to 20 years. Many leases also include options to terminate the leases within one year or per other contractual terms. The components of lease expense were as follows (in thousands): Year Ended December 31, 2022 2021 2020 Operating lease cost $ 25,874 $ 23,873 $ 19,842 Variable lease cost $ 8,569 $ 6,627 $ 5,335 Supplemental cash flow information related to the leases was as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 17,002 $ 16,266 $ 13,956 Right-of-use assets obtained in exchange for lease obligations: Operating leases 30,882 33,133 73,905 - 62 - Table of Contents Supplemental balance sheet information related to the leases was as follows at December 31 (in thousands): 2022 2021 Operating lease right-of-use assets $ 139,068 $ 129,558 Other current liabilities $ 19,272 $ 16,276 Operating lease liabilities 138,867 130,965 Total operating lease liabilities $ 158,139 $ 147,241 Weighted Average Remaining Lease Term (years) Operating leases 11.1 12.0 Weighted Average Discount Rate Operating leases 5.2 % 5.5 % Lease payments due related to lease liabilities as of December 31, 2022 were as follows (in thousands): Related Party Operating Leases Non-Related Parties Operating Leases Total Operating Leases 2023 $ 11,025 $ 15,079 $ 26,104 2024 11,154 12,439 23,593 2025 11,286 10,229 21,515 2026 11,422 8,904 20,326 2027 10,389 6,932 17,321 Later years 96,600 11,890 108,490 Total lease payments 151,876 65,473 217,349 Less: imputed interest ( 53,074 ) ( 6,136 ) ( 59,210 ) Total $ 98,802 $ 59,337 $ 158,139 9. SHAREHOLDERS’ EQUITY Stock-Based Compensation 2016 Incentive Award Plan On August 11, 2016 in connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (SARs), restricted stock awards (RSAs), restricted stock units (RSUs), or other cash based or stock dividend equivalent awards, which are all equity-classified instruments under the 2016 Plan. The number of shares registered and available for grant under the 2016 Plan is 6,000,000 . The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of the Company’s common stock at the date of grant and option terms are not expected to exceed ten years . The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the - 63 - Table of Contents first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. The Company granted 374,235 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2021, consisting of 74,725 RSU and 205,086 stock option awards vesting after four years and six months, 27,854 RSU and 9,000 stock option awards vesting after four years , and 57,570 stock option awards vesting after two years . The Company granted an additional 10,932 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2021. These awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. The Company granted 405,237 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2020, consisting of 20,724 RSA and 177,808 RSU vesting after four years , 4,800 stock option awards and 2,500 RSU vesting after three years and 199,405 fully-vested stock option awards. The Company granted an additional 23,148 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2020. These awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. The 2016 Plan expires in 2026, except for awards then outstanding, and is administered by the Board. All Awards granted at the IPO or thereafter were or will be issued under the 2016 Plan. The Company satisfies stock option exercises and vested stock awards with treasury shares or newly issued shares. Shares available for future stock compensation grants under the 2016 Plan totaled 2.3 million and 2.6 million at December 31, 2022 and 2021, respectively. 2014 Equity Incentive Plan The 2014 Plan for employees and directors provided the issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock. The awards were granted to key employees as additional compensation for services rendered and as a means of retention over the vesting period, typically three to four years . RSAs awarded under the 2014 Plan were subject to automatic forfeiture upon departure until vested and entitle the shareholder to all rights of common stock ownership except that they may not be sold, transferred, pledged or otherwise disposed of during the restriction period, except as noted in the following paragraph. The 2014 Plan allowed for the issuance of non-qualified stock options to employees, officers, and directors under this plan. Under the 2014 Plan, options could be granted with an exercise price equal to or greater than the fair value of common stock at the grant date as determined by the Board of Directors. The stock options, if unexercised, expired seven years from the date of grant. The awards under the 2014 Plan were equity classified instruments for all periods presented. There were no outstanding awards under the 2014 Plan as of December 31, 2022. Equity Awards Valuation Assumptions The Company determines the fair value of stock options using the Black-Scholes-Merton option pricing model (the “BSM Model”). The BSM Model is primarily affected by the fair value of the Company’s common stock (see restricted share valuation discussion below), the expected holding period for the option, expected stock price volatility over the term of the awards, the risk-free interest rate, and expected dividends. The following table sets forth the key weighted-average assumptions used in the BSM Model to calculate the fair value of options: Year Ended December 31, 2022 2021 2020 Expected holding period - years 4.7 5.0 3.1 Expected volatility 36.5 % 34.3 % 31.0 % Risk-free interest rate 1.9 % 0.9 % 1.0 % Expected dividend yield 0.0 % 0.0 % 0.0 % - 64 - Table of Contents The assumptions used in the table above reflect grant date inputs to arrive at the grant date fair values for stock options subject to equity-classified stock compensation accounting. The expected holding period represents the period of time the grants are expected to be outstanding. The Company uses the simplified method, as prescribed by accounting guidance governing such awards, to calculate the expected holding period for options granted to employees as we do not have sufficient historical evidence data to provide a reasonable basis upon which to estimate the expected holding period. For options valued by the Company for the years ended December 31, 2022, 2021 and 2020, respectively, the expected holding period is based on an average between the midpoint of the vesting date and the expiration date of the options. Due to the lack of Company specific historical and implied volatility data, our estimate of expected volatility is based upon a blended approach that utilizes the historical volatility of the Company's common stock for periods in which the Company has sufficient information and the historical volatility of a group of peer companies that are most representative of our company. The risk-free interest rate is based on the yield on U.S. Treasury obligations with remaining durations equal to the expected holding period of the options. The expected dividend yield is assumed to be zero based on recent and anticipated dividend activity. Subsequent to the Company’s IPO in August 2016, the fair value of common stock is based upon the market price of the Company’s common stock on the date of grant as listed on the NASDAQ. Due to the absence of an active market for the Company’s common stock prior to the IPO, the Company determined the fair value of restricted shares by obtaining an independent valuation of the fair value of the Company’s equity, applying a discount for lack of marketability, and then calculating the implied share price. The fair value of the Company was estimated primarily using an income approach which is based on assumptions and estimates made by management and, secondarily, using other market-related factors in current industry trends as well as observed transaction values. In determining the estimated future cash flows used in the income approach, the Company developed and applied certain estimates and judgments, including current and projected future levels of income based on management’s plans, business trends, prospects and market and economic conditions, including market-participant considerations. Significant assumptions utilized in the income approach were based on company specific information and projections, which were not observable in the market and are thus considered Level 3 measurements by authoritative guidance. The discount for lack of marketability (the “Marketability Discount”) was applied to reflect what a market participant would consider in relation to the post-vesting restrictions imposed regarding the inability to sell, transfer, or pledge the shares during the restriction period. The Marketability Discount was estimated by using the BSM Model to calculate the cost of a theoretical put option to hedge the fluctuation in value of the investment between the valuation date and an anticipated liquidity date. The following table summarizes the grant date fair values of stock options and restricted shares issued during the period as well as the allocation of stock-based compensation expense to Total direct costs, and Selling, general and administrative reported in the consolidated statements of operations: Year Ended December 31, 2022 2021 2020 Weighted average, grant date fair value Stock options $ 47.57 $ 52.70 $ 15.19 Restricted shares (RSAs and RSUs) $ 149.87 $ 174.94 $ 98.61 Stock-based compensation expense allocated to: Total direct costs $ 11,801 $ 9,345 $ 7,781 Selling, general, and administrative 9,611 5,124 6,003 Total stock-based compensation expense $ 21,412 $ 14,469 $ 13,784 - 65 - Table of Contents Award Activity The following table sets forth the Company’s stock option activity: Year Ended December 31, 2022 2021 2020 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options Weighted Average Exercise Price Outstanding - beginning of Period 1,992,915 $ 68.39 2,500,727 $ 43.26 3,030,071 $ 34.50 Granted 252,490 $ 138.91 282,588 $ 168.34 227,353 $ 105.77 Exercised ( 579,407 ) $ 38.10 ( 745,572 ) $ 23.67 ( 637,806 ) $ 25.07 Cancelled/Forfeited/Expired ( 36,850 ) $ 85.40 ( 44,828 ) $ 40.50 ( 118,891 ) $ 37.16 Outstanding - end of period 1,629,148 $ 89.71 1,992,915 $ 68.39 2,500,727 $ 43.26 Exercisable - end of period 1,116,255 $ 60.52 1,290,627 $ 56.43 1,498,829 $ 48.99 The following table sets forth the Company’s Restricted Share activity: Year Ended December 31, 2022 2021 2020 Shares/Units Shares/Units Shares/Units Outstanding and unvested - beginning of period 602,187 695,562 569,770 Granted 165,595 102,579 201,032 Vested ( 197,000 ) ( 119,000 ) — Forfeited ( 47,405 ) ( 76,954 ) ( 75,240 ) Outstanding and unvested - end of period 523,377 602,187 695,562 Cumulative vested shares - end of period 2,229,916 2,032,916 1,913,916 The following table summarizes information about stock options expected to vest, stock options exercisable, and unvested restricted share awards expected to vest at December 31, 2022: Weighted Average Exercise Price Stock Options Restricted Shares/Units Weighted Average Remaining Life (Years) Number of stock options expected to vest $ 89.71 1,629,148 — 3.3 Number of restricted shares/units expected to vest 523,377 Total expected to vest 1,629,148 523,377 Total stock options exercisable $ 60.52 1,116,255 — 2.5 Unrecognized compensation cost (in thousands) $ 14,989 $ 33,310 Weighted average years over which unrecognized compensation cost will be recognized 2.4 2.9 - 66 - Table of Contents The following table sets forth the aggregate intrinsic value of stock options exercised, the fair values of awards vested, and share based liabilities settled during the respective periods (in thousands): Year Ended December 31, 2022 2021 2020 Total intrinsic value of stock options exercised $ 77,527 $ 104,695 $ 57,927 Total grant-date fair value of stock options vested $ 5,228 $ 5,185 $ 6,833 Total grant-date fair value of restricted shares vested $ 9,248 $ 3,796 $ — Total settlement date fair value of restricted shares vested $ 32,802 $ 22,321 $ — The actual tax benefits recognized related to stock-based compensation totaled $ 23.2 million, $ 20.9 million and $ 11.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. 10. EMPLOYEE BENEFIT PLANS The Company provides a 401(k) plan that covers substantially all U.S. employees. Participants can elect to contribute up to 50 % of their eligible earnings on a pre-tax basis, subject to Internal Revenue Service annual limitations. The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 5.4 million, $ 4.3 million and $ 3.7 million during the years ended December 31, 2022, 2021 and 2020, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 2.5 million, $ 1.9 million and $ 1.5 million in the years ended December 31, 2022, 2021 and 2020, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. The Company is also required to pay certain minimum statutory post-employment benefits. The Company recognizes a liability and the associated expense for these benefits when it is probable that employees are entitled to the benefit. 11. INCOME TAXES The Company files income tax returns for U.S. federal and various U.S. states, as well as various foreign jurisdictions. The liabilities for unrecognized tax benefits are carried in Other long-term liabilities on the consolidated balance sheets because the payment of cash is not anticipated within one year of the balance sheet date. The components of income before income taxes consisted of the following (in thousands): Year Ended December 31, 2022 2021 2020 Domestic $ 260,564 $ 187,535 $ 158,432 Foreign jurisdictions 22,296 14,317 10,100 Income before income taxes $ 282,860 $ 201,852 $ 168,532 - 67 - Table of Contents Income tax provision consisted of the following (in thousands): Current Deferred Total Year ended December 31, 2022 U.S. Federal $ 49,991 $ ( 19,705 ) $ 30,286 U.S. state and local 7,160 ( 3,297 ) 3,863 Foreign jurisdictions 3,330 13 3,343 $ 60,481 $ ( 22,989 ) $ 37,492 Year ended December 31, 2021 U.S. Federal $ 46,138 $ ( 32,677 ) $ 13,461 U.S. state and local 8,405 ( 3,622 ) 4,783 Foreign jurisdictions 2,580 ( 820 ) 1,760 $ 57,123 $ ( 37,119 ) $ 20,004 Year ended December 31, 2020 U.S. Federal $ 16,405 $ 436 $ 16,841 U.S. state and local 4,588 95 4,683 Foreign jurisdictions 1,586 38 1,624 $ 22,579 $ 569 $ 23,148 - 68 - Table of Contents The difference between the statutory rate for federal income tax and the effective income tax rate was as follows (in thousands): Year Ended December 31, 2022 2021 2020 Income tax expense calculated at the federal statutory rate $ 59,401 21.0 % $ 42,389 21.0 % $ 35,392 21.0 % Effect of: State and local taxes, net of federal benefit 4,235 1.5 3,698 1.8 2,639 1.6 Tax on foreign earnings, net of tax credits and deductions ( 3,277 ) ( 1.2 ) ( 3,113 ) ( 1.5 ) ( 1,773 ) ( 1.1 ) Deferred credit ( 621 ) ( 0.2 ) ( 667 ) ( 0.3 ) ( 700 ) ( 0.4 ) Permanent items: Stock-based awards ( 18,738 ) ( 6.6 ) ( 19,042 ) ( 9.5 ) ( 10,019 ) ( 5.9 ) Deduction for FDII ( 4,983 ) ( 1.8 ) ( 4,860 ) ( 2.4 ) ( 2,593 ) ( 1.5 ) Other 595 0.2 ( 364 ) ( 0.2 ) 144 0.1 State/Local tax credits ( 1,294 ) ( 0.5 ) ( 976 ) ( 0.5 ) ( 780 ) ( 0.5 ) Change in liability for uncertain tax positions 1,560 0.6 2,349 1.2 1,120 0.7 Other 614 0.3 590 0.3 ( 282 ) ( 0.3 ) $ 37,492 13.3 % $ 20,004 9.9 % $ 23,148 13.7 % Prior to the passage of the Tax Cuts and Jobs Act of 2017 ("TCJA"), the Company asserted that all of the undistributed foreign earnings of its foreign subsidiaries were considered indefinitely reinvested and accordingly, no deferred taxes were provided. Beginning in 2018, the TCJA provides a 100 % deduction for dividends received from 10 -percent owned foreign corporations by U.S. corporate shareholders, subject to a one-year holding period. Although dividend income is now exempt from U.S. federal tax in the hands of the U.S. corporate shareholders, companies must still apply the guidance of ASC 740-30-25-18 to account for the tax consequences of outside basis differences and other tax impacts of their investments in non-U.S. subsidiaries. As of December 31, 2022, the Company’s accounting position is that unremitted foreign earnings are indefinitely reinvested. Therefore, the Company has not recorded deferred foreign withholding taxes on the unremitted foreign earnings and it is not practicable to determine the amount of the additional taxes that would result if these earnings were repatriated. The undistributed earnings of foreign subsidiaries was approximately $ 51.6 million for the year ended December 31, 2022. - 69 - Table of Contents Components of the Company’s net deferred tax asset (liability) included in the consolidated balance sheets consisted of the following at December 31 (in thousands): 2022 2021 Deferred tax assets: Accrued liabilities $ 24,483 $ 21,028 Depreciation and amortization 1,269 989 Foreign operating loss carryforward 30 386 Advanced billings 67,789 37,226 Other 1,005 1,148 Valuation allowance ( 430 ) ( 850 ) Total deferred tax assets 94,146 59,927 Deferred tax liabilities: Depreciation and amortization ( 44,731 ) ( 34,065 ) Prepaid expenses ( 1,263 ) ( 1,292 ) Other ( 1,139 ) ( 516 ) Total deferred tax liabilities ( 47,133 ) ( 35,873 ) Net deferred tax asset (liability) $ 47,013 $ 24,054 The Company has foreign operating loss carryforwards for which a deferred tax asset of less than $0.1 million has been established as of December 31, 2022. The Company does not have a valuation allowance against this deferred tax asset as of December 31, 2022 based upon its assessment that it is more likely than not that this amount will be realized. The ultimate realization of this tax benefit is dependent upon the generation of sufficient operating income in the respective tax jurisdictions. Approximately 57 % of the foreign net operating loss carryforwards can be utilized over an indefinite period whereas the remainder will expire in 2026 if not utilized. Annual activity related to the Company’s valuation allowance is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Beginning Balance $ 850 $ 578 $ 755 Additions charged to expense 15 305 — Reductions from utilization, reassessments and expirations ( 493 ) ( 33 ) ( 177 ) Remeasurement due to effect of tax reform 58 — — Ending Balance $ 430 $ 850 $ 578 A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Beginning Balance $ 13,784 $ 10,691 $ 9,718 Increases in tax positions for prior years 171 1,253 — Decreases in tax positions for prior years ( 490 ) ( 223 ) ( 181 ) Increases in tax positions for current year 4,871 3,098 2,881 Lapse in statute of limitations ( 2,389 ) ( 1,035 ) ( 1,727 ) Ending Balance $ 15,947 $ 13,784 $ 10,691 - 70 - Table of Contents Interest and penalties associated with uncertain tax positions are recognized as components of Income tax provision in the consolidated statements of operations. There was no material change to tax-related interest and penalties during the years ended December 31, 2022, 2021 and 2020. As of December 31, 2022 and 2021, respectively, the Company has a liability for interest and penalties of $ 3.8 million and $ 2.8 million that is associated with related tax liabilities of $ 12.7 million and $ 11.0 million for uncertain tax positions. The Company operates in various foreign, state and local jurisdictions. The number of tax years for which the statute of limitations remains open for foreign, state and local jurisdictions varies by jurisdiction and is approximately four years ( 2018 through 2022 ). For federal tax purposes, the Company’s open tax years are 2019 through 2022 . 12. COMMITMENTS, CONTINGENCIES, AND GUARANTEES Legal Proceedings Medpace periodically becomes involved in various claims and lawsuits that are incidental to its business. Management believes, after consultation with counsel, that no matters currently pending would, in the event of an adverse outcome, have a material impact on the Company’s consolidated balance sheets, statements of operations, or cash flows for the years ended December 31, 2022, 2021 and 2020. Purchase Commitments The Company has several minimum purchase commitments for project related supplies totaling $ 17.0 million as of December 31, 2022. In return for the commitment, Medpace receives preferential pricing. The commitments expire at various times through 2029. 13. MISCELLANEOUS INCOME, NET Miscellaneous income, net consisted of the following (in thousands): Year Ended December 31, 2022 2021 2020 Net gain on foreign-currency transactions $ 3,859 $ 2,779 $ 514 Other income 3,209 563 669 Miscellaneous income, net $ 7,068 $ 3,342 $ 1,183 14. RELATED PARTY TRANSACTIONS Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $ 0.3 million and $ 0.2 million existed at December 31, 2022 and 2021, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the consolidated balance sheets, respectively, depending on the contractual repayment date. Service Agreements LIB Therapeutics LLC and subsidiaries (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 40.5 million, $ 11.8 million and $ 2.6 million during the years ended December 31, 2022, 2021 and 2020, respectively, in the Company’s consolidated statement of operations. As of December 31, 2022 and 2021, the Company had, from LIB, Advanced billings of $ 7.4 million and $ 2.9 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of - 71 - Table of Contents $ 5.5 million and $ 0.5 million in the consolidated balance sheets at December 31, 2022 and 2021, respectively. The Company had Other current liabilities with LIB of $ 12.5 million in the consolidated balance sheets at December 31, 2022. CinRX Pharma, subsidiaries and affiliates (“CinRx”) Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2022, 2021 and 2020, the Company recognized total revenue from CinRx of $ 15.0 million, $ 22.7 million and $ 13.2 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2022 and 2021, the Company had Advanced billings from CinRx of $ 1.4 million and $ 5.4 million in the consolidated balance sheets, respectively. As of December 31, 2022 and 2021 the Company had Accounts receivable and unbilled, net from CinRx of $ 2.2 million and $ 2.1 million in the consolidated balance sheets, respectively. Certain affiliates of CinRx included in previous reported quarters are no longer disclosed due to changes in the affiliate relationship. The Summit Hotel (“The Summit”) The Summit Hotel, located on the Medpace campus, is owned by the chief executive officer. Medpace incurs travel lodging and meeting expenses at The Summit. During the years ended December 31, 2022, 2021 and 2020, Medpace incurred expenses of $ 0.3 million, $ 0.3 million and $ 0.4 million at The Summit, respectively. Leased Real Estate Headquarters Lease The Company has entered into operating leases for its corporate headquarters and a storage space facility with an entity that is wholly owned by the Company’s chief executive officer. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease for headquarters was for an initial term of twelve years through November 2022 with a renewal option for one 10 -year term at prevailing market rates. The Company entered into short-term extensions through January 2023. In the third quarter of fiscal year 2021, the Company accounted for the renewal option, as it became reasonably certain it would be exercised per the agreement, by extending the lease term through November 2032. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. Operating lease cost recognized for the years ended December 31, 2022, 2021 and 2020 was $ 2.3 million, $ 2.1 million and 2.0 million, respectively, and was allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2022 and 2021 were $ 18.2 million and $ 19.7 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2022 were $ 1.5 million and $ 16.7 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2021 were $ 1.5 million and $ 18.3 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2022, 2021 and 2020 was $ 5.7 million, $ 5.7 million and $ 3.6 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2022 and 2021 were $ 53.5 million and $ 55.1 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2022 were $ 1.1 million and $ 64.8 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2021 were $ 0.9 million and $ 65.9 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. - 72 - Table of Contents The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the leases are operating leases. Operating lease cost recognized for the years ended December 31, 2022, 2021 and 2020 was $ 3.6 million, respectively. The lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2022 and 2021 were $ 14.6 million and $ 17.2 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2022 were $ 2.8 million and $ 11.9 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2021 were $ 2.6 million and $ 14.6 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. Travel Services The Company incurs expenses for travel services for company executives provided by private aviation charter companies which in 2020 was a company owned by the chief executive officer and the executive vice president of operations of the Company and commencing in 2021 is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 2.3 million, $ 1.3 million and $ 0.7 million during the years ended December 31, 2022, 2021 and 2020, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2022 and 2021, the Company had Accounts payable to the Aircraft Management Company of $ 0.3 million and $ 0.2 million, respectively, in the consolidated balance sheets. 15. ENTITY WIDE DISCLOSURES Operations By Geographic Location The Company conducts operations in North America, Europe, Asia, South America, Africa and Australia through wholly-owned subsidiaries and representative sales offices. The Company attributes revenue to geographical locations based upon the location of the contracting entity. For the years ended December 31, 2022, 2021 and 2020, total revenue attributable to the U.S. represented approximately 98 %, 97 % and 96 %, respectively, of total consolidated total revenue. The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, if any (in thousands): 2022 2021 Property and equipment, net: United States $ 81,217 $ 64,828 Europe Belgium 11,778 12,339 Other 9,294 8,413 Total Europe 21,072 20,752 Other 7,560 7,573 Total property and equipment, net $ 109,849 $ 93,153 Revenue by Category The following table disaggregates the Company’s revenue by major source (in thousands): - 73 - Table of Contents Years Ended December 31, 2022 2021 2020 Therapeutic Area Oncology $ 467,796 $ 362,846 $ 297,675 Other 296,914 267,415 215,370 Metabolic 244,682 159,900 126,075 Cardiology 174,634 119,692 95,153 Central Nervous System 157,939 121,548 88,393 AVAI 118,031 110,976 103,259 Total revenue $ 1,459,996 $ 1,142,377 $ 925,925 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure None.